Colloidal Silver, Treatment of COVID-19

Hôpital Universitaire Sahloul

Status: Unknown

Conditions: SARS (Severe Acute Respiratory Syndrome)

Treatments: Drug: Colloidal Silver; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04978025

colloidal silver and COVID-19

Details and patient eligibility

About

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities I

Full description

Noble metals such as gold and silver have been appreciated for millennia not only for their beauty but also for their ability to fight diseases.

Silver nanoparticles (AgNPs) have been employed as chemical drugs thanks to their unique physiochemical and chemical properties as well as biological features, such as anti-inflammatory, anti-angiogenesis, antiplatelet, antifungal, anti-cancer and antibacterial activities Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy.

The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) .

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inclusion of any patient, over the age of 18, consulting the Sahloul emergencies, Sousse for symptoms of COVID -19 dating less than 10 days and having a positive COVID-19 on the PCR test and typical scanner.

Exclusion criteria

• Any pregnant or breastfeeding woman
• patient with an expectation of survival of less than 24 hours
• Dyspnea leading to heart failure
• Hepatic insufficiency
• Chronic respiratory failure
• Renal failure, clearance <20ml • min-1 • 1.73 • m-²

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups, including a placebo group

Silver Group

Experimental group

Description:

* Orally: the colloidal agent 1 dose of 30ml, 3 times a day for 5 days (use a plastic measuring cup and not a measuring cup or a metal spoon) * By inhalation: nebulization of 5ml of colloidal silver solution once, 3 times a day for 5 days.

Treatment:

Drug: Colloidal Silver

Placebo Group

Placebo Comparator group

Description:

* Orally: EPPI 1 dose of 30 ml, 3 times a day for 5 days * By inhalation: nebulization of 5ml of EPPI solution once a day, 3 times a day for 5 days.

Treatment:

Drug: Placebo